BPC-157: UK and US regulatory context
The October 2026 US announcement does not authorise BPC-157 as a medicine in the UK. Whether a particular product falls within UK medicines regulation depends on its presentation and properties, assessed under the UK framework. A research-use label alone cannot settle that question.
What did HHS publish in October 2026?
The US Federal Register notice dated 30 October announces a draft enforcement-discretion policy for certain peptide substances used in compounding under section 503A. It describes specified pharmacy and physician compounding while the relevant substances list is developed through rulemaking. It also says compounded medicines are not FDA-approved. Read the official notice.
The notice invites comments for two weeks after publication. It is not a UK decision, and the end of a comment window should not be read as an approval date. The linked HHS policy and appendices set out the substances and conditions addressed by the document. The six-peptide reference introduces the names discussed in this policy.
How does the MHRA decide whether a product is a medicine?
The MHRA's borderline-products guidance, updated on 2 July 2026, describes two routes into the medicinal-product definition: presentation as preventing or treating disease, and specified pharmacological, immunological or metabolic functions.
The agency considers explicit and implied claims, the ingredients' properties, intended purpose and how consumers would use the product. That is a broader assessment than reading one line on a label. The underlying definition appears in regulation 2 of the Human Medicines Regulations 2012.
Which question does each source answer?
| Question | Relevant source | What not to infer |
|---|---|---|
| What does the US compounding policy address? | HHS notice and policy | That it authorises UK supply or human use |
| When is a product a medicine in the UK? | MHRA guidance and UK legislation | That a research-use label is decisive |
| How are advertising claims assessed? | ASA rules and findings | That a disclaimer overrides the whole advertisement |
| Is a substance prohibited in sport? | WADA list and UKAD guidance | That medicine status answers the anti-doping question |
The ASA report article covers advertising, while the 2027 WADA and UKAD explainer covers the separate sports rules. The BPC-157 reference concerns material identity and evidence.
So is BPC-157 legal to buy or use?
An answer needs to identify the activity and the particular product. Sale, advertising, importation, possession and administration are different questions; this article does not determine the lawfulness of an individual transaction. Neither a US policy headline nor a supplier's description is a substitute for the applicable UK requirements. A batch certificate addresses an analytical sample, not permission for a use.
This is a report on the cited documents, not individual legal advice.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.